Sodium sulfite promotes the assembly and secretion of very low-density lipoprotein in HL-7702 hepatocytes



==Highlights==
* Na<sub>2</sub> SO<sub>3</sub>  can increase the secretion of VLDL and apoB100 of human hepatocytes.                              
* Na<sub>2</sub> SO<sub>3</sub>  can increase the expression of MTP and TGH in human hepatocytes.                              
* Na<sub>2</sub> SO<sub>3</sub>  can not increase TG levels inside the human hepatocytes, but can increase the extracellular TG level.      

==Abstract==

This study investigated the effects of Na<sub>2</sub> SO<sub>3</sub>  on the fat metabolism in human normal diploid HL-7702 (referred as L-02) hepatocytes. After 24 h and 48 h, treatment with different concentrations of Na<sub>2</sub> SO<sub>3</sub> , the intra and extra-hepatocellular triglyceride (TG) contents of L-02 were determined using chemical-enzymatic method. The contents of very low-density lipoprotein (VLDL) and apolipoprotein B100 (apoB100) in the culture supernatants were determined using enzyme-linked immunosorbent assay (ELISA). Western blot was applied to detect the expressions of fatty acid oxidation and fat synthesis related proteins, VLDL assembly and secretion in L-02 cells.          

====Results====

Na<sub>2</sub> SO<sub>3</sub>  treatment (10 mM, 24 h/48 h) significantly increased the intra TG level in the hepatocytes. Different concentrations of Na<sub>2</sub> SO<sub>3</sub>  increased the extra-hepatocellular TG content. After 24 h exposure, the extracellular VLDL levels and secretions of apoB100 in 0.1–10 mM Na<sub>2</sub> SO<sub>3</sub>  groups were significantly higher than that of the negative control (''P '' < 0.05). Meanwhile, the expression of CPT1 and SREBP1 protein were significantly reduced by Na<sub>2</sub> SO<sub>3</sub> . MTP and TGH protein expressions were significantly elevated in each Na<sub>2</sub> SO<sub>3</sub>  treatment group. The expression level of LDLR in hepatocytes was reduced by Na<sub>2</sub> SO<sub>3</sub> .          

====Conclusion====

Na<sub>2</sub> SO<sub>3</sub>  exposure may promote the hepatocellular VLDL assembly and secretion, through increasing of MTP and TGH expressions and inhibiting the uptake of extracelluar VLDL.  

==Abbreviation==

TG , triglyceride ; VLDL , very low-density lipoprotein ; apoB100 , apolipoprotein B100 ; ELISA , enzyme-linked immunosorbent assay ; CPT1 , carnitine palmitoyl transferase 1 ; SREBP1 , sterol regulatory element binding protein-1 ; MTP , microsomal triglyceride transfer protein ; TGH , triglyceride hydrolase ; Arf1 , ADP-ribosylation factor-1 ; COP I , coated protein I ; LDLR , low-density lipoprotein receptor ; NAFLD , Nonalcoholic fatty liver disease

==Keywords==

Sodium sulfite ; Hepatocytes ; VLDL ; Fatty acid oxidation ; Fat synthesis ; VLDL uptake

==1. Introduction==

Na<sub>2</sub> SO<sub>3</sub>  is the main residue in traditional food and pharmaceutical products after sulfur fumigation. It is widely used as an additive in various dried fruits (such as pistachio nuts, preserved fruit, etc.), pharmaceutical products and alcoholic drinks [[#bib0005|[1]]]  and [[#bib0010|[2]]] . Sulfur dioxide can be transformed to Na<sub>2</sub> SO<sub>3</sub>  after inhalation via respiratory tract; eventually this compound enters other organs including the liver and kidney via the blood circulation [[#bib0015|[3]]] .      

However, extensive studies have reported that Na<sub>2</sub> SO<sub>3</sub>  is able to damage the respiratory, cardiovascular and nervous systems [[#bib0020|[4]]] , [[#bib0025|[5]]]  and [[#bib0030|[6]]] . For example, respiratory system diseases caused by Na<sub>2</sub> SO<sub>3</sub>  including asthma [[#bib0040|[8]]] , [[#bib0045|[9]]]  and [[#bib0050|[10]]] , chronic mucous hypersecretion, cough, rhintis, bronchitis [[#bib0055|[11]]]  and [[#bib0060|[12]]]  and even lung cancer [[#bib0035|[7]]] . Na<sub>2</sub> SO<sub>3</sub>  exposure can also increase the mortality of cardiovascular disease [[#bib0065|[13]]]  and the risk of acute stroke [[#bib0070|[14]]] . Na<sub>2</sub> SO<sub>3</sub>  can impair nervous system by causing synaptic injury, spatial learning and memory impairment and an increase in reactive oxygen species and a decrease in ATP in Neuro-2a and PC12 cells [[#bib0025|[5]]] , [[#bib0030|[6]]]  and [[#bib0075|[15]]] . However, It is reported that deficiency of sulphite oxidase could lead to mental retardation, neurological symptoms such as spastic quadriplegia, and early death [[#bib0080|[16]]]  and [[#bib0085|[17]]] . In particular, Na<sub>2</sub> SO<sub>3</sub>  is more dangerous to sensitive individuals, Vally et al. reported that topical, oral or parenteral Na<sub>2</sub> SO<sub>3</sub>  exposure induces a range of adverse clinical effects, ranging from dermatitis, urticaria, flushing, hypotension, abdominal pain and diarrhoea to life-threatening anaphylactic and asthmatic reactions in sensitive individuals [[#bib0090|[18]]] .      

Although different organs have different reactivities to Na<sub>2</sub> SO<sub>3</sub> , but they also share some similar mechanisms to Na<sub>2</sub> SO<sub>3</sub>  injury. For example, Na<sub>2</sub> SO<sub>3</sub>  exposure can change the redox state in liver, kidney and nervous system [[#bib0095|[19]]] , [[#bib0100|[20]]]  and [[#bib0105|[21]]] . Some studies have reported that mice might become hyperlipidemic after exposure to sulfur dioxide, and triglyceride (TG) content in hepatocytes was increased [[#bib0110|[22]]]  and [[#bib0115|[23]]] , Bai and Meng. suggested that Na<sub>2</sub> SO<sub>3</sub>  may cause metabolic disorders in mice hepatocytes.The molecular mechanism of Na<sub>2</sub> SO<sub>3</sub>  influence on fat metabolic disorders in human liver remains unclear. Because both extrahepatic and intrahepatic factors cause fat metabolic disorders [[#bib0140|[28]]] , Nonalcoholic fatty liver disease (NAFLD) is now threatening growing number of people both in developed and developing countries [[#bib0120|[24]]] , [[#bib0130|[26]]]  and [[#bib0135|[27]]] . Our study targets on the intrahepatic factors include abnormalities in fat synthesis and fatty acid decomposition of the hepatocytes, as well as abnormal assembly and secretion of very low-density lipoprotein (VLDL) [[#bib0145|[29]]] . The most studied fat synthesis regulation protein is sterol regulatory element binding protein-1(SREBP1), which chiefly regulates the synthesis of fatty acids [[#bib0150|[30]]]  and the key enzyme of fatty acid decomposition is carnitine palmitoyl transferase 1(CPT1b) in liver [[#bib0155|[31]]] . The VLDL assembly and secretion related proteins includes MTP, TGH, Arf1 and COP I, etc. [[#bib0160|[32]]] , [[#bib0170|[34]]] , [[#bib0175|[35]]]  and [[#bib0180|[36]]] . In the present study, in vitro experiments were used to investigate the changes of above intrahepatic factors associated with fat metabolism after treating L-02 hepatocytes with different concentrations of Na<sub>2</sub> SO<sub>3</sub> .      

<span id='sec0010'></span>
==2. Materials and methods==

===2.1. Materials===

The normal human diploid hepatocytes (HL-7702; referred as L-02) were purchased from Shanghai Institute of Cell Biology, Chinese Academy of Sciences, China. Fetal calf serum and high glucose Dulbeccos modified Eagles medium (DMEM) were from Hyclone. Na<sub>2</sub> SO<sub>3</sub> , oleic acid, and tryptase were bought from Sigma. Pre-stained protein marker was obtained from Fermentas, Western blot substrate was from Thermo Scientific, human very low-density lipoprotein (VLDL) (ESK5997) and human apolipoprotein B100 (apoB100) (ESK5994) test kit were purchased from Shanghai Sangon Biological Engineering Technology & Services Co., Ltd., China. TG assay Kit (GPO-POD method) were bought from Applygen Technologies Inc., China.      

The primary and secondary antibodies used in this study is listed in [[#tbl0005|Table 1]]  and [[#tbl0010|Table 2]] .

<span id='tbl0005'></span>

{| class="wikitable" style="min-width: 60%;margin-left: auto; margin-right: auto;"
|+

Table 1.

Primary antibodies used in western blot.

|-

! Primary antibody
! Company
! Catalogue #
! Dilution
|-

! Rabbit anti-human MTP
| Abcam
| Ab63467
| 1:1000
|-

! Rabbit anti-human LDLR
| Abcam
| Ab52818
| 1:1000
|-

! Rabbit anti-human COP β
| Abcam
| Ab2899
| 1:1000
|-

! Rabbit anti-human TGH
| Abcam
| Ab68190
| 1:3000
|-

! Rabbit anti-human Arf1
| Epitomics
| #1635-1
| 1:2000
|-

! Rabbit anti-human CPT1a
| Protein Tech, China
| 15184-1-AP
| 1:1000
|-

! Rabbit anti-human SREBP1c
| Protein Tech, China
| 14088-1-AP
| 1:1000
|-

! Mouse anti-human β-actin
| Wuhan Boster Biological Technology Co., Ltd., China
| BM0005
| 1:1000
|}

<span id='tbl0010'></span>

{| class="wikitable" style="min-width: 60%;margin-left: auto; margin-right: auto;"
|+

Table 2.

Secondary antibodies used in western blot.

|-

! Secondary antibody
! Company
! Catalogue #
! Dilution
|-

! Goat anti-rabbit IgG
| Wuhan Boster Biological Technology Co., Ltd., China
| BA1050
| 1:4000
|-

! Goat anti-mouse IgG
| Wuhan Boster Biological Technology Co., Ltd., China
| BA1055
| 1:4000
|}

===2.2. Culture and treatment of cells===

L-02 cells were cultured in high glucose DMEM containing 10% calf serum in an incubator at 5% CO<sub>2</sub>  and 37 °C. The medium was replaced every two-three days. Cells were digested and passaged with 0.25% trypsin. After achieving 80% adhesion, they were selected for the experiments. Seven treatment groups were set up as the followings: one negative control group (complete medium), four Na<sub>2</sub> SO<sub>3</sub>  treatment groups, and two positive control groups (1 mM oleic acid group and 10 mM carbon tetrachloride group). The concentrations in the Na<sub>2</sub> SO<sub>3</sub>  treatment groups were configured as 10, 2.5, 0.5, and 0.1 mM according to previous report [[#bib0075|[15]]]  and [[#bib0185|[37]]] . Cells were routinely seeded onto a six-well culture plate, each group in two wells. The extracellular supernatants after exposure for 24 and 48 h were collected for detecting VLDL and apoB100 contents in the supernatant, and intracellular proteins were collected for protein expression analysis. All the experiments were repeated thrice for statistic analysis.      

===2.3. Detection of intra-hepatocellular TG level===

Detection of TG in hepatocytes was performed as reference with minor adjustment [[#bib0190|[38]]] . The cells were routinely seeded onto a 6-well culture plate. After treatment the supernatants were removed for further protein analysis. The cell pellets were washed with 2 ml PBS. They were dispersed with 400 μl of PBS/10 mM EDTA, pH 7.4. 200 μl of cell suspension was centrifuged and lysed for protein measurement. 200 μl of cell suspension was added to glass tubes with 2 ml of isopropanol–hexane–water (IHW) for organic extraction, vortexed and incubated with aluminum foil for 30 min. Then 500 μl of hexane–diethyl ether (1:1) was added to each tube. Samples were vortexed, incubated and covered with aluminum foil for 10 min at room temperature. 1 ml of water was added to separate phases by vortexing. Another incubation covered with aluminum foil until phases separate (∼20 min) at room temperature. The organic phase (900 μl) was pipetted into a new glass tube for nitrogen evaporation using a 96-well format manifold at 50 °C. Then 10 μl water and 190 μl of TG reagent were added to each tube according to the instruction. The tubes were vortexed and covered with parafilm and incubated for 30 min at 37 °C with shaking at 100 rpm. Finally 150 μl of TG reagent with samples was dispensed to a flat-bottom 96-well plastic microplate to determine absorbance at 550 nm.      

===2.4. Determination of extra-hepatocellular TG content===

The cells were routinely seeded onto a 24-well culture plate, each treatment group in two wells. The supernatants were collected after exposure for 24 and 48 h, and the TG was extracted using organic extraction method similar to intracellular TG detection, evaporated by using a 96-pin microplate format gas manifold [[#bib0190|[38]]] . 1 ml of supernatant was used for extraction instead of 200 μl of cell suspension. The TG level was determined according to the instructions provided along with the kit, and the experiment was repeated 4 times.      

===2.5. Detection of secretions of VLDL and apoB100 of hepatocytes treated with Na<sub>2</sub> SO<sub>3</sub>===

VLDL and apoB100 in the supernatant was detected according to the instructions provided with the kit.

===2.6. Detection of protein expression===

The intracellular proteins were collected using the loading buffer after exposure for 24 and 48 h, and quantified by using trichloroacetic acid method. A loading amount of 25–50 μg protein sample was collected for sodium dodecyl sulfate-polyacrylamide gel electrophoresis using 10 or 15% separating gel and 5% spacer gel. Separated proteins were transferred electronically to nitrocellulose membrane. Membrane was blocked with 5% defatted milk powder at room temperature for 1 h. Blocked membranes were incubated with corresponding first antibody (CPT1a 1:1000, SREBP1c 1:1000, MTP 1:1000, TGH 1:3000, Arf1 1:2000, COP β 1:1000, LDLR 1:1000, β-actin 1:1000) in a 4 °C shaker overnight. Later the membranes were shaken and rinsed thrice with phosphate-buffered saline with Tween 20 (PBST) at room temperature. Secondary antibody coupled with horse radish peroxidase (goat anti-rabbit 1:4000 and goat anti-mouse 1:4000) was added and incubated at room temperature for 1 h. The protein expression was detected using enhanced chemiluminescence. β-actin was detected for loading control of same amount of total protein. Films were developed, the optical density in hybridization maps was semiquantitatively analyzed using Image-Pro Plus 6.0 software.

===2.7. Statistical analysis===

Statistical analyses were performed using SPSS17.0 software, and the results were expressed as mean ± standard error. One-factor analysis of variance was used to compare the mean values of various groups. Multiple comparisons between groups were performed using Dunnetts ''t''  test. A difference with ''P '' < 0.05 was considered statistically significant.      

==3. Results==

===3.1. Na<sub>2</sub> SO<sub>3</sub>  has no significant effects on intra-hepatocellular TG level of human L-02                        ===

Na<sub>2</sub> SO<sub>3</sub>  could increase lipid droplets in mouse [[#bib0110|[22]]] , herein we examined its effects on the TG level in human hepatocytes. The present results showed that TG level in hepatocytes treated by 0.1 mM–2.5 mM Na<sub>2</sub> SO<sub>3</sub>  was not significantly increased, but the TG level in hepatocytes was increased significantly by 10 mM Na<sub>2</sub> SO<sub>3</sub>  24 h/48 h exposure, accompanied by cell death ([[#tbl0015|Table 3]] ).

<span id='tbl0015'></span>

{| class="wikitable" style="min-width: 60%;margin-left: auto; margin-right: auto;"
|+

Table 3.

Effect of Na<sub>2</sub> SO<sub>3</sub>  treatment on the TG level of L-02 hepatocytes (''n''  = 3, <math display="inline">\overline{x}\pm s</math> ).                  

|-

! Group
! colspan="2" | TG (mmol g<sup>−1</sup> )
|-

! 
! 24 h
! 48 h
|-

! Negative control
| 1.2218 ± 0.5272
| 1.4837 ± 0.1236
|-

! 0.1mM Na2SO3
| 1.2609 ± 0.4914
| 1.3167 ± 0.2209
|-

! 0.5mM Na2SO3
| 1.5099 ± 0.3047
| 1.9047 ± 0.5721
|-

! 2.5mM Na2SO3
| 1.8227 ± 0.4524
| 2.1050 ± 0.3275
|-

! 10.0mM Na2SO3
| 2.4713 ± 0.7691*
| 6.3060 ± 0.8734*
|-

! 1.0mM OA
| 3.0940 ± 0.7968*
| 3.0130 ± 0.6844*
|-

! 10.0mM CCl4
| 3.2353 ± 1.1168*
| 1.8090 ± 0.5705
|}

Cells were treated with Na<sub>2</sub> SO<sub>3</sub>  (as described in Section [[#sec0010|2]] ), the lipids in the cells were extracted with hexane-isopropanol-diethyl ether, and quantified.      

*. ''P '' < 0.05 when compared to negative control.              

===3.2. Na<sub>2</sub> SO<sub>3</sub>  increases extra-hepatocellular TG level of human L-02                        ===

TG content in extra-hepatocytes was detected by GPO-POD method. The present results showed that TG level in the supernatant of hepatocytes was significantly increased when treated by 0.1mM–10 mM Na<sub>2</sub> SO<sub>3</sub> , (<sup>*</sup>''P '' < 0.05). As control settings, OA or CCl<sub>4</sub>  treatment also increased the TG content in the supernatant ([[#tbl0020|Table 4]] ). It means that Na<sub>2</sub> SO<sub>3</sub>  can increase the secretion of TG from hepatocytes.

<span id='tbl0020'></span>

{| class="wikitable" style="min-width: 60%;margin-left: auto; margin-right: auto;"
|+

Table 4.

Effect of Na<sub>2</sub> SO<sub>3</sub>  treatment on the secretion of TG from L-02 hepatocytes (''n''  = 4, <math display="inline">\overline{x}\pm s</math> ).                  

|-

! Group
! colspan="2" | TG(mmol/L)
|-

! 
! 24 h
! 48 h
|-

! Negative control
| 0.1203 ± 0.0354
| 0.5245 ± 0.0333
|-

! 0.1mM Na2SO3
| 0.5557 ± 0.1606*
| 0.6326 ± 0.1369*
|-

! 0.5mM Na2SO3
| 0.6477 ± 0.1084*
| 0.5881 ± 0.0633*
|-

! 2.5mM Na2SO3
| 0.5991 ± 0.1107*
| 0.6311 ± 0.0707*
|-

! 10.0mM Na2SO3
| 0.6399 ± 0.0759*
| 0.7501 ± 0.0990*
|-

! 1.0mM OA
| 0.4586 ± 0.0453*
| 1.0816 ± 0.0111*
|-

! 10.0mM CCl4
| 0.7163 ± 0.0879*
| 0.7027 ± 0.0948*
|}

Cells were treated with Na<sub>2</sub> SO<sub>3</sub>  (as described in Section [[#sec0010|2]] ), the lipids in the supernatants were extracted with hexane-isopropanol-diethyl ether, and quantified.      

*. ''P '' < 0.05 when compared to negative control.              

===3.3. Na<sub>2</sub> SO<sub>3</sub>  promotes secretion of VLDL in L-02 hepatocytes                        ===

As illustrated in [[#tbl0025|Table 5]] , after 24 h exposure to Na<sub>2</sub> SO<sub>3</sub> , VLDL content in the supernatant of each Na<sub>2</sub> SO<sub>3</sub>  group was significantly increased as compared with the negative control (''P '' < 0.05). This result suggests that Na<sub>2</sub> SO<sub>3</sub>  promotes the secretion of VLDL in hepatocytes. However, after exposure to Na<sub>2</sub> SO<sub>3</sub>  for 48 h, the VLDL content in each treatment group did not significantly change as compared with the negative control<sub>.</sub>

<span id='tbl0025'></span>

{| class="wikitable" style="min-width: 60%;margin-left: auto; margin-right: auto;"
|+

Table 5.

Effect of Na<sub>2</sub> SO<sub>3</sub>  treatment on the secretion of VLDL from L-02 hepatocytes (''n''  = 3, <math display="inline">\overline{x}\pm s</math> ).                  

|-

! Group
! colspan="2" | VLDL(μmol/L)
|-

! 
! 24 h
! 48 h
|-

! Negative control
| 242.08 ± 3.52
| 239.00 ± 7.05
|-

! 0.1mM Na2SO3
| 278.23 ± 6.01**
| 287.97 ± 14.21
|-

! 0.5mM Na2SO3
| 296.44 ± 2.47*
| 289.77 ± 29.08
|-

! 2.5mM Na2SO3
| 276.44 ± 33.09*
| 256.44 ± 25.48
|-

! 10.0mM Na2SO3
| 263.10 ± 10.24*
| 235.92 ± 32.31
|-

! 1.0mM OA
| 300.54 ± 12.66*
| 271.82 ± 36.20
|-

! 10.0mM CCl4
| 245.40 ± 15.46
| 237.46 ± 20.16
|}

Cells were treated with Na<sub>2</sub> SO<sub>3</sub>  (as described in Section 2), the supernatants were collected and VLDL contents were quantified.      

*. ''P '' < 0.05 when compared to negative control.              

===3.4. Na<sub>2</sub> SO<sub>3</sub>  promotes the secretion of apoB100 in L-02 hepatocytes                        ===

After exposure to Na<sub>2</sub> SO<sub>3</sub>  for 24 or 48 h, the apoB100 contents in the supernatant of extracellular medium were significantly increased as compared with the negative control group (''P '' < 0.05). This reflected that in a dose dependent manner, Na<sub>2</sub> SO<sub>3</sub>  can promote the secretion of apoB100 in hepatocytes.      

===3.5. Na<sub>2</sub> SO<sub>3</sub>  suppresses the expressions of CPT1 and SREBP1                        ===

CPT1 is a key rate-limiting enzyme for fatty acid decomposition in hepatocytes, and SREBP1 is an important transcription factor that promotes the expression of fat synthesis related genes. After exposure to Na<sub>2</sub> SO<sub>3</sub>  for 24 h and 48 h, the expressions of CPT1 protein in 0.1–10 mM Na<sub>2</sub> SO<sub>3</sub>  treatment groups were significantly reduced. This suggests that Na<sub>2</sub> SO<sub>3</sub>  exposure can suppress β-oxidation of hepatic fatty acids, which is conducive to the synthesis of TG. After exposure for 24 h, the expression of SREBP1 was decreased by Na<sub>2</sub> SO<sub>3</sub> ; while after 48 h exposure, the expressions of SREBP1 were significantly decreased in the 2.5–10 mM Na<sub>2</sub> SO<sub>3</sub>  groups. This similar responsiveness as OA treatment indicates that hepatocytes may counteract the risk of increased synthesis of TG.      

===3.6. Na<sub>2</sub> SO<sub>3</sub>  promotes the expression of TG transfer protein in L-02 hepatocytes                        ===

MTP is responsible for the assembly of TG and apoB100 to generate primary VLDL. TGH is responsible for hydrolysis and re-esterification of TG in endochylema of hepatocytes, followed by assembly with apoB100 to generate VLDL. At least 70% of the TG in the hepatocytes enters VLDL through this route. The initial products of VLDL are transported into the Golgi apparatus with the effects of Arf1 and COP I after their generation in the endoplasmic reticulum, followed by further processing for secretion. After exposure to Na<sub>2</sub> SO<sub>3</sub>  for 24 and 48 h, the expressions of MTP and TGH in each Na<sub>2</sub> SO<sub>3</sub>  group and positive control were significantly increased ([[#fig0010|Fig. 2]] a). The expressions of Arf1 and COP β protein were increased significantly after exposure to Na<sub>2</sub> SO<sub>3</sub>  for 48 h ([[#fig0010|Fig. 2]] b). The above results indicated that Na<sub>2</sub> SO<sub>3</sub>  may promote the expressions of MTP and TGH proteins, and in the same time upregulate Arf1 and COP β proteins for more VLDL secretion.

<span id='fig0010'></span>

{| style="text-align: center; border: 1px solid #BBB; margin: 1em auto; max-width: 100%;" 
|-
|


[[Image:draft_García_466667543-1-s2.0-S2214750015300949-gr2.jpg|center|px|Effect of Na2SO3 treatment on protein expression levels of VLDL assembly-related ...]]


|-
| <span style="text-align: center; font-size: 75%;">

Fig. 2.

Effect of Na<sub>2</sub> SO<sub>3</sub>  treatment on protein expression levels of VLDL assembly-related proteins (MTP and TGH) and transportation-related proteins (Arf1 and COP β) in L-02 hepatocytes. Cells were treated with Na<sub>2</sub> SO<sub>3</sub>  (as described in Section [[#sec0010|2]] ), proteins were collected, equal total protein levels were loaded by detection of β-actin as a reference, and levels were analyzed using western blot. The expressions of MTP and TGH in each Na<sub>2</sub> SO<sub>3</sub>  group and positive control were significantly increased after 24/48 h exposure. Arf1 and COP β were increased after 48 h exposure.                  

</span>
|}

===3.7. Na<sub>2</sub> SO<sub>3</sub>  inhibits the expression of LDLR protein in L-02 hepatocytes                        ===

The LDLR in the liver is primarily responsible for removal of LDL from the circulation. It has been speculated that LDLR affects plasma apoB containing lipoprotein (Blp) metabolism by uptake LDL from the plasma by apoB100 and apoE related pathway. It is also responsible for the uptake of VLDL in vitro. Similar to positive control (OA and CCl<sub>4</sub>  groups), Na<sub>2</sub> SO<sub>3</sub>  experimental groups have significant lower LDLR expression than the negative control ([[#fig0015|Fig. 3]] ). That means that Na<sub>2</sub> SO<sub>3</sub>  may inhibit the uptake of VLDL/LDL from the supernatant of L-02.

<span id='fig0015'></span>

{| style="text-align: center; border: 1px solid #BBB; margin: 1em auto; max-width: 100%;" 
|-
|


[[Image:draft_García_466667543-1-s2.0-S2214750015300949-gr3.jpg|center|376px|Effect of Na2SO3 treatment on protein expression level of LDLR.Cells were ...]]


|-
| <span style="text-align: center; font-size: 75%;">

Fig. 3.

Effect of Na<sub>2</sub> SO<sub>3</sub>  treatment on protein expression level of LDLR.                          

Cells were treated with Na<sub>2</sub> SO<sub>3</sub>  (as described in Section [[#sec0010|2]] ), proteins were collected, equal total protein levels were loaded by detection of β-actin as a reference, and levels were analyzed using western blot. LDLR expression was inhibited by Na<sub>2</sub> SO<sub>3</sub>  treatment for 24/48 h (similar as OA and CCl<sub>4</sub> ).                  

</span>
|}

==4. Discussion==

Na<sub>2</sub> SO<sub>3</sub>  is a common reductive food additive, but it is also a metabolic derivative of the air pollutant sulfur dioxide in the body. Previous animal experiments have found that inhalation of sulfur dioxide could increase hepatic lipid droplets and TG level and increase the plasmic TG content in mouse liver [[#bib0110|[22]]]  and [[#bib0115|[23]]] . We hypothesized that exposure to Na<sub>2</sub> SO<sub>3</sub>  may cause metabolic disorder of human liver, thereby lead to NAFLD by inhibition the secretion of VLDL. At present, NAFLD is a burgeoning health problem affecting one-third of adults and an increasing number of children in developed countries. The NAFLD begins with the aberrant accumulation of triglyceride in the liver. Some individuals elicits an inflammatory response that can progress to cirrhosis or liver cancer [[#bib0120|[24]]] , [[#bib0125|[25]]] , [[#bib0130|[26]]]  and [[#bib0135|[27]]] .      

In this study, both intra- and extra-hepatocellular TG contents from L-02 were examined after exposure to Na<sub>2</sub> SO<sub>3</sub> . The results showed that Na<sub>2</sub> SO<sub>3</sub>  has no direct effect on TG content in the human liver cells. At a higher concentration (10 mM), Na<sub>2</sub> SO<sub>3</sub>  significantly increased the TG content and cell death (75% for 24 h, 50% for 48 h, data not shown) ([[#tbl0015|Table 3]] ). But, Na<sub>2</sub> SO<sub>3</sub>  promotes the secretion and exocytosis of TG ([[#tbl0020|Table 4]] ). Our data suggest that Na<sub>2</sub> SO<sub>3</sub>  may not induce NAFLD directly. We also did not find the inhibition of VLDL secretion, on the contrary, the findings of the present study revealed that Na<sub>2</sub> SO<sub>3</sub>  was able to promote the secretions of VLDL and apoB100 ([[#tbl0025|Table 5]]  and [[#tbl0030|Table 6]] ).      

It was reported that the fat content in the hepatocytes is controlled by the decomposition of the fatty acid and synthetic rate of TG [[#bib0145|[29]]] . CPT1 is the key rate-limiting enzyme for the decomposition of fatty acid in hepatocytes. Suppression of CPT1 activity might lead to increased TG synthesis, thereby cause TG accumulation [[#bib0155|[31]]]  and [[#bib0195|[39]]] . Our data showed that the expression of CPT1 was significantly inhibited by Na<sub>2</sub> SO<sub>3</sub>  exposure ([[#fig0005|Fig. 1]] ), suggesting that Na<sub>2</sub> SO<sub>3</sub>  has the potential to increase the TG content in the hepatocytes. Interestingly, we did not find significant increase of TG in cells. Probably the inhibition of CPT1 is not strong enough or other counteract factors are involved in the TG processing. In this study, the expression of SREBP1c was markedly reduced after exposure to Na<sub>2</sub> SO<sub>3</sub>  similar to 1 mM OA treatment ([[#fig0005|Fig. 1]] ) [[#bib0200|[40]]] . SREBP1c mainly regulates the synthesis of fatty acids by enhancing transcription of the genes encoding acetyl CoA carboxylase, fatty acid synthase, stearoyl CoA desaturase-1 [[#bib0205|[41]]]  and [[#bib0210|[42]]] . Our results indicated that Na<sub>2</sub> SO<sub>3</sub>  may increase the synthesis of TG through the inhibition of CPT1. But hepatocytes can mobilize their protective mechanism to response to this possible adverse effect under mild threat. However, since in vitro experiments can only reflect the short-term effect of a toxicant on the body or cells, further in-depth studies are required to investigate long-term effect Na<sub>2</sub> SO<sub>3</sub>  exposure.

<span id='fig0005'></span>

{| style="text-align: center; border: 1px solid #BBB; margin: 1em auto; max-width: 100%;" 
|-
|


[[Image:draft_García_466667543-1-s2.0-S2214750015300949-gr1.jpg|center|393px|Effect of Na2SO3 treatment on protein expression levels of CPT1 and SREBP1 in ...]]


|-
| <span style="text-align: center; font-size: 75%;">

Fig. 1.

Effect of Na<sub>2</sub> SO<sub>3</sub>  treatment on protein expression levels of CPT1 and SREBP1 in L-02 hepatocytes. Cells were treated with Na<sub>2</sub> SO<sub>3</sub>  (as described in Section [[#sec0010|2]] ), proteins were collected, equal total protein levels were loaded, and levels were analyzed using western blot. The expression of CPT1 and SREBP1 was significantly reduced.                  

</span>
|}

In addition to fatty acid decomposition and fat synthesis, VLDL secretion is a key factor that affects the TG level in the hepatocytes [[#bib0215|[43]]] , [[#bib0140|[28]]]  and [[#bib0145|[29]]] . This study investigated the assembly and secretion of VLDL of L-02 hepatocytes after exposure to Na<sub>2</sub> SO<sub>3</sub> . After 24 h exposure, the VLDL content in the supernatant was significantly increased ([[#tbl0025|Table 5]] ). This result is consistent with our previous results using protein hybridization (data not shown), and further proved that Na<sub>2</sub> SO<sub>3</sub>  is prone to promote the secretion of VLDL. Meanwhile, it was also found that exposure to Na<sub>2</sub> SO<sub>3</sub>  could promote the secretion of apoB100 ([[#tbl0030|Table 6]] ).

<span id='tbl0030'></span>

{| class="wikitable" style="min-width: 60%;margin-left: auto; margin-right: auto;"
|+

Table 6.

Effect of Na<sub>2</sub> SO<sub>3</sub>  treatment on the secretion of apoB100 from L-02 hepatocytes (''n''  = 3, <math display="inline">\overline{x}\pm s</math> ).                  

|-

! Group
! colspan="2" | apoB100(ng/ml)
|-

! 
! 24 h
! 48 h
|-

! Negative control
| 135.13 ± 3.33
| 143.59 ± 13.44
|-

! 0.1mM Na2SO3
| 155.90 ± 6.63*
| 171.03 ± 3.62*
|-

! 0.5mM Na2SO3
| 177.95 ± 8.75*
| 197.69 ± 2.47*
|-

! 2.5mM Na2SO3
| 199.49 ± 2.35*
| 240.26 ± 3.33*
|-

! 10.0mM Na2SO3
| 235.64 ± 3.95*
| 255.13 ± 2.96*
|-

! 1.0mM OA
| 201.54 ± 5.81*
| 230.00 ± 5.40*
|-

! 10.0mM CCl4
| 231.79 ± 5.46*
| 263.33 ± 4.62*
|}

Cells were treated with Na<sub>2</sub> SO<sub>3</sub>  (as described in Section [[#sec0010|2]] ), the supernatants were collected, and apoB100 contents were quantified.      

*. ''P '' < 0.05 when compared to negative control.              

In normal physiological condition, TG should be effectively and properly assembled and transported before VLDL secretion. This complex process requires many important protein molecules. Our study mainly focused on four types of commonly recognized proteins, that is MTP, TGH, Arf1 and COPI. Initially, MTP was discovered to catalyze the transportation of neutral lipids, and serves as an essential molecule for the assembly and maturation of lipoprotein VLDL, which contains abundant apoB100 [[#bib0145|[29]]] , [[#bib0220|[44]]]  and [[#bib0225|[45]]] . Studies have found that inhibition of MTP activity by chemical inhibitor might lead to failure of VLDL assembly [[#bib0230|[46]]] , while the secretion of VLDL might be elevated with increased expression of MTP [[#bib0155|[31]]] . In this study, the expressions of MTP in the hepatocytes were significantly increased after exposure to Na<sub>2</sub> SO<sub>3</sub>  ([[#fig0010|Fig. 2]] ), thereby we speculate that MTP is associated with increased secretions of VLDL ([[#tbl0025|Table 5]] ) and apoB100([[#tbl0030|Table 6]] ) in the hepatocytes. TGH is involved in the hydrolysis and re-esterification of TG in the VLDL assembly [[#bib0170|[34]]] . More than 70% of the TG in the hepatocytes can be evacuated after hydrolysis and re-esterification. An elevated TGH expression in the hepatocytes may enhance its mobilization and the re-esterification [[#bib0235|[47]]]  and [[#bib0240|[48]]] . On the contrary, inhibition of TGH activity in the hepatocytes may lead to limited mobilization of TG and reduced secretion of VLDL [[#bib0165|[33]]] . Our study found that the expression of TGH was significantly increased after exposure to Na<sub>2</sub> SO<sub>3</sub>  suggesting that TGH alternation is associated with the increased Na<sub>2</sub> SO<sub>3</sub> -related secretions of VLDL and apoB100. The effects of Na<sub>2</sub> SO<sub>3</sub>  on the expressions of Arf1 and COP β proteins were also studied. Arf1 is an important molecule for sorting and transporting proteins from the endoplasmic reticulum to the Golgi apparatus. Arf1 can also facilitate the functions of mitochondria and endoplasmic reticulum [[#bib0245|[49]]]  and [[#bib0250|[50]]] . Arf1 is necessary for the movement of special secretory vesicles VLDL precursor from the endoplasmic reticulum to cis-face of the Golgi apparatus, where an overexpression of Arf1 might promote the secretion of VLDL [[#bib0175|[35]]] . COP β is one of COPI' s subunits. This experiment showed that Na<sub>2</sub> SO<sub>3</sub>  promotes the expression of Arf1 and COPβ, suggesting that they are associated with the promoting effect of Na<sub>2</sub> SO<sub>3</sub>  on secretions of apoB100.      

We observed increased VLDL content in the supernatant after Na<sub>2</sub> SO<sub>3</sub>  exposure. LDLR is transcriptionally regulated by the sterol regulatory element binding protein 2 (SREBP-2). LDLR is also post-translationally regulated by proprotein convertase subtilisin/kexin-type 9 (PCSK9) and inducible degrader of the LDLR (IDOL) [[#bib0255|[51]]] , [[#bib0260|[52]]] , [[#bib0265|[53]]] , [[#bib0270|[54]]]  and [[#bib0275|[55]]] . We found that Na<sub>2</sub> SO<sub>3</sub>  decreased the expression of LDLR, it means that it can inhibit the uptake of VLDL in the supernatant. It may also contribute to the increase of VLDL and apoB100 in the supernatant.      

In summary, this study indicated that exposure to Na<sub>2</sub> SO<sub>3</sub>  has little effects on the fat accumulation in human hepatocytes. However, Na<sub>2</sub> SO<sub>3</sub>  may promote the secretions of VLDL and apoB100, and increase the expressions of MTP and TGH. As these proteins are related to VLDL assembly, our results indicate that Na<sub>2</sub> SO<sub>3</sub>  may promote the secretions of VLDL and apoB100 through MTP and TGH pathway. This study also suggests that exposure of Na<sub>2</sub> SO<sub>3</sub>  may decrease the expression to LDLR which may contribute to the increase of VLDL secretion.      

==Conflict of interest==

The authors declare that there are no conflicts of interest.

==Acknowledgements==

This work was funded by NSFC  ([[#gs0005|30972445]] ) and Shanxi Province Foundation for Retruness  ([[#gs0010|2014-034]] ) and Natural Science Foundation of Shanxi Province of China  ([[#gs0015|2007011109]] ). We thank Yan Zhang and Pan Wang from Shanxi medical university for help of western blot test.

==References==

<ol style='list-style-type: none;margin-left: 0px;'><li><span id='bib0005'></span>
[[#bib0005|[1]]] A. Gunnison; Sulphite toxicity: a critical review of in vitro and in vivo data; Food Chem. Toxicol., 9 (5) (1981), pp. 667–682</li>
<li><span id='bib0010'></span>
[[#bib0010|[2]]] H. Mitsuhashi, H. Ikeuchi, Y. Nojima; Is sulfite an antiatherogenic compound in wine?; Clin. Chem., 47 (10) (2001), pp. 1872–1873</li>
<li><span id='bib0015'></span>
[[#bib0015|[3]]] R. Shapiro; Genetic effects of bisulfite (sulfur dioxide); Mutat. Res., 38 (1977), pp. 149–175</li>
<li><span id='bib0020'></span>
[[#bib0020|[4]]] R.E. Reus, G.F. Houben, M. Stam, A.E. Dubois; Food additives as a cause of medical symptoms: relationship shown between sulfites and asthma and anaphylaxis: results of a literature review; Ned. Tijdschr. Geneeskd., 144 (38) (2000), pp. 1836–1839</li>
<li><span id='bib0025'></span>
[[#bib0025|[5]]] G. Yao, Y. Yun, N. Sang; Differential effects between one week and four weeks exposure to same mass of SO<sub>2</sub>  on synaptic plasticity in rat hippocampus                                        ; Environ. Toxicol. (2014) [http://dx.doi.org/10.1002/tox.22093 http://dx.doi.org/10.1002/tox.22093]</li>
<li><span id='bib0030'></span>
[[#bib0030|[6]]] G. Yao, H. Yue, Y. Yun, N. Sang; Chronic SO2 inhalation above environmental standard impairs neuronal behavior and represses glutamate receptor gene expression and memory-related kinase activation via neuroinflammation in rats; Environ. Res., 137 (2015), pp. 85–93</li>
<li><span id='bib0035'></span>
[[#bib0035|[7]]] W.J. Lee, K. Teschke, T. Kauppinen, A. Andersen, P. Jäppinen, I. Szadkowska-Stanczyk, N. Pearce, B. Persson, A. Bergeret, L.A. Facchini, R. Kishi, D. Kielkowski, B.A. Rix, P. Henneberger, J. Sunyer, D. Colin, M. Kogevinas, P. Boffetta; Mortality from lung cancer in workers exposed to sulfur dioxide in the pulp and paper industry; Environ. Health Perspect., 110 (10) (2002), pp. 991–995</li>
<li><span id='bib0040'></span>
[[#bib0040|[8]]] E. Levetin, P. Van de Water; Environmental contributions to allergic disease; Curr Allergy Asthma Rep., 1 (6) (2001), pp. 506–514</li>
<li><span id='bib0045'></span>
[[#bib0045|[9]]] R.J. Pandya, G. Solomon, A. Kinner, J.R. Balmes; Diesel exhaust and asthma: hypotheses and molecular mechanisms of action; Environ. Health Perspect., 110 (Suppl. 1) (2002), pp. 103–112</li>
<li><span id='bib0050'></span>
[[#bib0050|[10]]] A.P. Jones; Asthma and home environment; J. Asthma, 37 (2) (2000), pp. 103–124</li>
<li><span id='bib0055'></span>
[[#bib0055|[11]]] J. Heinrich, B. Hoelscher, C. Frye, I. Meyer, M. Pitz, J. Cyrys, M. Wjst, L. Neas, H.E. Wichmann; Improved air quality in reunified Germany and decreases in respiratory symptoms; Epidemiology, 13 (4) (2002), pp. 394–401</li>
<li><span id='bib0060'></span>
[[#bib0060|[12]]] T. Koshino, K.R. Bhaskar, L.M. Reid, C. Gerard, A. Warner, S.A. Shore, K. Anderson, G. Butler, H. Iijima, J.M. Drazen; Recovery of an epitope recognized by a novel monoclonal antibody from airway lavage during experimental induction of chronic bronchitis; Am. J. Respir. Cell Mol. Biol., 2 (5) (1990), pp. 453–462</li>
<li><span id='bib0065'></span>
[[#bib0065|[13]]] T.F. Mar, G.A. Norris, J.Q. Koenig, T.V. Larson; Associations between air pollution and mortality in Phoenix, 1995-1997; Environ. Health Perspect., 108 (4) (2000), pp. 347–353</li>
<li><span id='bib0070'></span>
[[#bib0070|[14]]] Y.C. Hong, J.T. Lee, H. Kim, E.H. Ha, J. Schwartz, D.C. Christiani; Effects of air pollutants on stroke mortality; Environ. Health Perspect., 110 (2) (2002), pp. 187–191</li>
<li><span id='bib0075'></span>
[[#bib0075|[15]]] X. Zhang, A.S. Vincent, B. Halliwell, K.P. Wong; A mechanism of sulfite neurotoxicity: direct inhibition of glutamate dehydrogenase; J. Biol. Chem., 279 (41) (2004), pp. 43035–43045</li>
<li><span id='bib0080'></span>
[[#bib0080|[16]]] P. Tardy, P. Parvy, C. Charpentier, J.P. Bonnefont, J.M. Saudubray, P. Kamoun; Attempt at therapy in sulphite oxidase deficiency; J. Inherit. Metab. Dis., 12 (1) (1989), pp. 94–95</li>
<li><span id='bib0085'></span>
[[#bib0085|[17]]] F. Irreverre, S.H. Mudd, W.D. Heizer, L. Laster; Sulfite oxidase deficiency: studies of a patient with mental retardation, dislocated ocular lenses, and abnormal urinary excretion of ''S'' -sulfo-l -cysteine, sulfite, and thiosulfate                                        ; Biochem. Med., 1 (2) (1967), pp. 187–217</li>
<li><span id='bib0090'></span>
[[#bib0090|[18]]] H. Vally, N.L. Misso, V. Madan; Clinical effects of sulphite additives; Clin. Exp. Allergy, 39 (11) (2009), pp. 1643–1651</li>
<li><span id='bib0095'></span>
[[#bib0095|[19]]] O. Elmas, M. Aslan, S. Caglar, N. Derin, A. Agar, Y. Alicigüzel, P. Yargiçoğlu; The prooxidant effect of sodium metabisulfite in rat liver and kidney; Regul. Toxicol. Pharmacol., 42 (1) (2005), pp. 77–82</li>
<li><span id='bib0100'></span>
[[#bib0100|[20]]] H. Niknahad, P.J. O'Brien; Mechanism of sulfite cytotoxicity in isolated rat hepatocytes; Chem. Biol. Interact., 174 (3) (2008), pp. 147–154</li>
<li><span id='bib0105'></span>
[[#bib0105|[21]]] Z. Meng; Oxidative damage of sulfur dioxide on various organs of mice: sulfur dioxide is a systemic oxidative damage agent; Inhal. Toxicol., 15 (2003), pp. 181–195</li>
<li><span id='bib0110'></span>
[[#bib0110|[22]]] J.Y. Bai, Z.Q. Meng; Sulfur dioxide-induced liver pathology; Zhonghua Bing Li Xue Za Zhi, 33 (2) (2004), pp. 155–157</li>
<li><span id='bib0115'></span>
[[#bib0115|[23]]] M.R. Lovati, C. Manzonic, M. Daldossi, S. Spolti, C.R. Sirtori; Effects of sub-chronic exposure to SO<sub>2</sub>  on lipid and carbohydrate metabolism in rats                                        ; J. Arch. Toxicol., 70 (3–4) (1996), pp. 164–173</li>
<li><span id='bib0120'></span>
[[#bib0120|[24]]] B.Q. Starley, C.J. Calcagno, S.A. Harrison; Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection; Hepatology, 51 (5) (2010), pp. 1820–1832</li>
<li><span id='bib0125'></span>
[[#bib0125|[25]]] R.B. Perumpail, R.J. Wong, A. Ahmed, S.A. Harrison; Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US experience; Dig. Dis. Sci., 60 (10) (2015), pp. 3142–3148</li>
<li><span id='bib0130'></span>
[[#bib0130|[26]]] J. Wang, C. Xu, Y. Xun, Z. Lu, J. Shi, C. Yu, Y. Li; ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population; Sci. Rep., 16 (5) (2015), p. 16494</li>
<li><span id='bib0135'></span>
[[#bib0135|[27]]] J.G. Fan, G.C. Farrell; Epidemiology of non-alcoholic fatty liver disease in China; J. Hepatol., 50 (1) (2009), pp. 204–210</li>
<li><span id='bib0140'></span>
[[#bib0140|[28]]] P. Nguyen, V. Leray, M. Diez, S. Serisier, J. Le Bloc'h, B. Siliart, H. Dumon; Liver lipid metabolism; J. Anim. Physiol. Anim. Nutr. (Berl.), 92 (3) (2008), pp. 272–283</li>
<li><span id='bib0145'></span>
[[#bib0145|[29]]] J.C. Cohen, J.D. Horton, H.H. Hobbs; Human fatty liver disease: old questions and new insights; Science, 332 (6037) (2011), pp. 1519–1523</li>
<li><span id='bib0150'></span>
[[#bib0150|[30]]] G.L. Wang, Y.C. Fu, W.C. Xu, Y.Q. Feng, S.R. Fang, X.H. Zhou; Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway; Biochem. Biophys. Res. Commun., 380 (3) (2009), pp. 644–649</li>
<li><span id='bib0155'></span>
[[#bib0155|[31]]] D.H. Kim, T. Zhang, S. Lee, V. Calabuig-Navarro, J. Yamauchi, A. Piccirillo, Y. Fan, R. Uppala, E. Goetzman, H.H. Dong; FoxO6 integrates insulin signaling with MTP for regulating VLDL production in the liver; Endocrinology, 155 (4) (2014), pp. 1255–1267</li>
<li><span id='bib0160'></span>
[[#bib0160|[32]]] U.J. Tietge, A. Bakillah, C. Maugeais, K. Tsukamoto, M. Hussain, D.J. Rader; Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased in vivo secretion of VLDL triglycerides and apolipoprotein B; J. Lipid Res., 40 (11) (1999), pp. 2134–2139</li>
<li><span id='bib0165'></span>
[[#bib0165|[33]]] D. Gilham, M. Alam, W. Gao, D.E. Vance, R. Lehner; Triacylglycerol hydrolase is localized to the endoplasmic reticulum by an unusual retrieval sequence where it participates in VLDL assembly without utilizing VLDL lipids as substrates; Mol. Biol. Cell, 16 (2) (2005), pp. 984–996</li>
<li><span id='bib0170'></span>
[[#bib0170|[34]]] V.W. Dolinsky, D. Gilham, M. Alam, D.E. Vance, R. Lehner; Triacylglycerol hydrolase: role in intracellular lipid metabolism; Cell. Mol. Life Sci., 61 (13) (2004), pp. 1633–1651</li>
<li><span id='bib0175'></span>
[[#bib0175|[35]]] L. Asp, B. Magnusson, M. Rutberg, L. Li, J. Borén, S.O. Olofsson; Role of ADP ribosylation factor 1 in the assembly and secretion of ApoB-100-containing lipoproteins; Arterioscler. Thromb. Vasc. Biol., 25 (3) (2005), pp. 566–570</li>
<li><span id='bib0180'></span>
[[#bib0180|[36]]] S. Bouvet, M.P. Golinelli-Cohen, V. Contremoulins, C.L. Jackson; Targeting of the Arf-GEF GBF1 to lipid droplets and Golgi membranes; J. Cell Sci., 126 (Pt. 20) (2013), pp. 4794–4805</li>
<li><span id='bib0185'></span>
[[#bib0185|[37]]] M. Pelletier, V. Lavastre, D. Girard; Activation of human epithelial lung A549 cells by the pollutant sodium sulfite: enhancement of neutrophil adhesion; Toxicol. Sci., 69 (1) (2002), pp. 210–216</li>
<li><span id='bib0190'></span>
[[#bib0190|[38]]] D.M. Schwartz, N.E. Wolins; A simple and rapid method to assay triacylglycerol in cells and tissues; J. Lipid Res., 48 (11) (2007), pp. 2514–2520</li>
<li><span id='bib0195'></span>
[[#bib0195|[39]]] L.Y. Chen, B. Yang, L. Zhou, F. Ren, Z.P. Duan, Y.J. Ma; Promotion of mitochondrial energy metabolism during hepatocyte apoptosis in a rat model of acute liver failure; Mol. Med. Rep., 12 (2015), pp. 5035–5041</li>
<li><span id='bib0200'></span>
[[#bib0200|[40]]] N. Ziamajidi, S. Khaghani, G. Hassanzadeh, S. Vardasbi, S. Ahmadian, A. Nowrouzi, S.M. Ghaffari, A. Abdirad; Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1; Food Chem. Toxicol., 58 (2013), pp. 198–209</li>
<li><span id='bib0205'></span>
[[#bib0205|[41]]] J. Han, E. Li, L. Chen, Y. Zhang, F. Wei, J. Liu, H. Deng, Y. Wang; The CREB coactivator CRTC2 controls hepatic lipid metabolism by regulating SREBP1; Nature, 524 (7564) (2015), pp. 243–246</li>
<li><span id='bib0210'></span>
[[#bib0210|[42]]] A. Bitter, A.K. Nüssler, W.E. Thasler, K. Klein, U.M. Zanger, M. Schwab, O. Burk; Human sterol regulatory element-binding protein 1a contributes significantly to hepatic lipogenic gene expression; Cell. Physiol. Biochem., 35 (2) (2015), pp. 803–815</li>
<li><span id='bib0215'></span>
[[#bib0215|[43]]] M. Schonewille, G. Brufau, R. Shiri-Sverdlov, A.K. Groen, J. Plat; Serum TG-lowering properties of plant sterols and stanols are associated with decreased hepatic VLDL secretion; J. Lipid Res., 55 (12) (2014), pp. 2554–2561</li>
<li><span id='bib0220'></span>
[[#bib0220|[44]]] M.M. Hussain, J. Shi, P. Dreizen; Microsomal triglyceride transfer protein and its role in apoB- lipoprotein assembly; J. Lipid Res., 44 (1) (2003), pp. 22–32</li>
<li><span id='bib0225'></span>
[[#bib0225|[45]]] A.J. Hooper, L.A. Adams, J.R. Burnett; Genetic determinants of hepatic steatosis in man; J. Lipid Res., 52 (4) (2011), pp. 593–617</li>
<li><span id='bib0230'></span>
[[#bib0230|[46]]] B. Magnusson, L. Asp, P. Bostrom, M. Ruiz, P. Stillemark-Billton, D. Lindén, J. Borén, S.O. Olofsson; Adipocyte differentiation related protein promotes fatty acid storage in cytosolic triglycerides and inhibits secretion of very low density lipoproteins; Arterioscler. Thromb. Vasc. Biol., 26 (7) (2006), pp. 1566–1571</li>
<li><span id='bib0235'></span>
[[#bib0235|[47]]] J. Lian, E. Wei, S.P. Wang, A.D. Quiroga, L. Li, A. Di Pardo, J. van der Veen, S. Sipione, G.A. Mitchell, R. Lehner; Liver specific inactivation of carboxylesterase 3/triacylglycerol hydrolase decreases blood lipids without causing severe steatosis in mice; Hepatology, 56 (6) (2012), pp. 2154–2162</li>
<li><span id='bib0240'></span>
[[#bib0240|[48]]] R. Lehner, D.E. Vance; Cloning and expression of a cDNA encoding a hepatic microsomal lipase that mobilizes stored triacylglycerol; Biochem. J., 343 (Pt. 1) (1999), pp. 1–10</li>
<li><span id='bib0245'></span>
[[#bib0245|[49]]] I. Kufareva, M. Lenoir, F. Dancea, P. Sridhar, E. Raush, C. Bissig, J. Gruenberg, R. Abagyan, M. Overduin; Discovery of novel membrane binding structures and functions; Biochem. Cell Biol., 92 (6) (2014), pp. 555–563</li>
<li><span id='bib0250'></span>
[[#bib0250|[50]]] K.B. Ackema, J. Hench, S. Böckler, S.C. Wang, U. Sauder, H. Mergentaler, B. Westermann, F. Bard, S. Frank, A. Spang; The small GTPase Arf1 modulates mitochondrial morphology and function; EMBO J., 33 (22) (2014), pp. 2659–2675</li>
<li><span id='bib0255'></span>
[[#bib0255|[51]]] A. Pirillo, AL.Berberine Catapano; Berberine a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies; Atherosclerosis, 243 (2) (2015), pp. 449–461</li>
<li><span id='bib0260'></span>
[[#bib0260|[52]]] N. Zelcer, C. Hong, R. Boyadjian, P. Tontonoz; LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor; Science, 325 (5936) (2009), pp. 100–104</li>
<li><span id='bib0265'></span>
[[#bib0265|[53]]] M. Abifadel, M. Varret, J.P. Rabès, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, A. Derré, L. Villéger, M. Farnier, I. Beucler, E. Bruckert, J. Chambaz, B. Chanu, J.M. Lecerf, G. Luc, P. Moulin, J. Weissenbach, A. Prat, M. Krempf, C. Junien, N.G. Seidah, C. Boileau; Mutations in PCSK9 cause autosomal dominant hypercholesterolemia; Nat. Genet., 34 (2) (2003), pp. 154–156</li>
<li><span id='bib0270'></span>
[[#bib0270|[54]]] J. Guillemot, M.C. Asselin, D. Susan-Resiga, R. Essalmani, N.G. Seidah; Deferoxamine stimulates LDLR expression and LDL uptake in HepG2 cells; Mol. Nutr. Food Res. (November) (2015) [http://dx.doi.org/10.1002/mnfr.201500467 http://dx.doi.org/10.1002/mnfr.201500467]</li>
<li><span id='bib0275'></span>
[[#bib0275|[55]]] R. Caraballo, M. Larsson, S.K. Nilsson, M. Ericsson, W. Qian, N.P. Nguyen Tran, T. Kindahl, R. Svensson, V. Saar, P. Artursson, G. Olivecrona, P.A. Enquist, M. Elofsson; Structure-activity relationships for lipoprotein lipase agonists that lower plasma triglycerides in vivo; Eur. J. Med. Chem., 103 (2015), pp. 191–209</li>
</ol>